Polycythemia vera secondary prevention: Difference between revisions
Mahshid |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia vera}} | {{Polycythemia vera}} | ||
{{CMG}}{{AE}} {{MJK}} | {{CMG}}{{AE}} {{MJK}} {{shyam}} | ||
{{SK}} Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia | {{SK}} Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia | ||
==Overview== | ==Overview== | ||
Secondary prevention strategy following polycythemia vera include low dose [[aspirin]]. | Secondary prevention strategy following polycythemia vera include low dose [[aspirin]]. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Secondary prevention strategy following polycythemia vera include low dose aspirin to decrease the risk of the following complications:<ref name="pmid16462024">{{cite journal| author=Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I| title=Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. | journal=Biol Pharm Bull | year= 2006 | volume= 29 | issue= 2 | pages= 234-9 | pmid=16462024 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16462024 }} </ref> | Secondary prevention strategy following polycythemia vera include low-dose aspirin 81mg daily to decrease the risk of the following complications:<ref name="pmid16462024">{{cite journal| author=Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I| title=Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. | journal=Biol Pharm Bull | year= 2006 | volume= 29 | issue= 2 | pages= 234-9 | pmid=16462024 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16462024 }} </ref> | ||
*[[Cardiovascular]] death | *[[Cardiovascular]] death | ||
*Non-fatal [[myocardial infarction]] | *Non-fatal [[myocardial infarction]] | ||
Latest revision as of 04:29, 19 February 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera secondary prevention |
|
Risk calculators and risk factors for Polycythemia vera secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3] Synonyms and keywords: Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia
Overview
Secondary prevention strategy following polycythemia vera include low dose aspirin.
Secondary Prevention
Secondary prevention strategy following polycythemia vera include low-dose aspirin 81mg daily to decrease the risk of the following complications:[1]
- Cardiovascular death
- Non-fatal myocardial infarction
- Non-fatal stroke
References
- ↑ Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I (2006). "Role of polyamines derived from arginine in differentiation and proliferation of human blood cells". Biol Pharm Bull. 29 (2): 234–9. PMID 16462024.